MedTrace Logo

Scan-rescan Reproducibility of Myelin Sensitive MRI Techniques

NCT04673734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2021-12-15

No results posted yet for this study

Summary

This study is to assess the variation in the measurements of myelin sensitive MRI techniques in both white and grey matter in the brain.

Conditions

  • Myelin Integrity

Interventions

DIAGNOSTIC_TEST

myelin sensitive MRI scan

Acquisition of 3 myelin sensitive MRI scans as follows: 1. Two MRI during 1 day; the second after 30 min interval and a repositioning. 2\. One MRI within one week after the first one. The total scan time will be \~ 1 hour. T1 maps will be calculated after magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE6) acquisition based on a product sequence. Magnetization Transfer (MT) sat maps will be calculated. Quantitative susceptibility mapping (QSM) maps will be reconstructed using an in-house implementation of the structural feature based collaborative reconstruction algorithm (SFCR). For the reconstruction of multi-shell diffusion data, AMICO10 Accelerated Microstructure Imaging via Convex Optimization (AMICO) from diffusion MRI data will be used. Myelin Water Fraction maps will be fitted voxel-wise using a Non-Negative Least Squares fitting.

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Cristina Granziera, Prof. Dr. med. · Neurologische Klinik und Poliklinik, University Hospital Basel

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-05
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673734 on ClinicalTrials.gov